SCHEMBL7026752

SCHEMBL7026752

O=c1c2[nH]c(N3CCOCC3)nc2n(CC2CC2)c(=O)n1CC1CC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 9/20 0.60
PDE4B Q07343 9/20 0.60
PDE4C Q08493 9/20 0.60
PDE4D Q08499 9/20 0.60
PDE5A O76074 8/20 0.60
SIRT1 Q96EB6 1/20 0.55
SIRT3 Q9NTG7 1/20 0.55
SIRT5 Q9NXA8 1/20 0.55
ADORA1 P30542 4/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
TSHR P16473 2/20 0.47
ADORA2A P29274 2/20 0.44
ADORA2B P29275 2/20 0.44
ADORA3 P0DMS8 1/20 0.40
PIM1 P11309 1/20 0.40
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7025747 0.89 ADORA1 (0.64) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7025779 0.88 ADORA1 (0.65) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7107683 0.87 ADORA1 (0.56) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7032150 0.84 ADORA1 (0.64) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL8836691 0.80 ADORA1 (0.79) SIRT1SIRT3SIRT5ADORA1MEN1
SCHEMBL7398584 0.79 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DPDE5A
Cipamfylline SCHEMBL26990 0.75 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7809025 0.75 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL7026234 0.75 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL10816927 0.74 MEN1 (0.61) PDE4APDE4BPDE4CPDE4DSIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 EP claimed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 US claimed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 EP claimed
US-6531600-B1 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed BEECHAM GROUP P.L.C. (GB) 2003-03-11 US disclosed
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 EP disclosed
US-6180791-B1 REDUCING NITRO GROUPS TO FORM AMINO GROUPS BEECHAM GROUP P.L.C. (GB) 2001-01-30 US disclosed
US-5981535-A FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-09 US disclosed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 US disclosed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 EP disclosed